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Abstract
OBJECTIVE—Evaluate the association between fetal inflammation and coagulation gene single-
nucleotide polymorphisms (SNPs) and neurodevelopmental delay at age 2.
METHODS—Case-control secondary analysis of a randomized trial of single- versus multiple-
course corticosteroids. Multiplex assay assessed 46 SNPs. Cases had mental developmental and/or
psychomotor delay at age 2. Controls had normal neurodevelopment.
RESULTS—125 cases and 147 controls were analyzed. Allele frequencies were different between
cases and controls for IL1-β –511 (p=0.009), IL4R 148 (p=0.03), IL6 -174 (p=0.02), and IL6 -176
(p=0.007). Genotype frequencies were different for IL1-β-511 (p=0.03) and IL6 -174 (p=0.04).
Results for IL1-β –511, IL4R 148, and IL6 -176 remained significant after logistic regression
analysis. IL1-β-511 and IL6 -176 minor alleles were associated with increased risk of
neurodevelopmental delay, OR 3.1 (1.2–8.2) and 2.2 (1.2–3.9), respectively. IL4R 148 minor allele
was protective, OR 0.6 (0.4–0.9).
CONCLUSION—Fetal SNPs in IL1-β, IL4R and IL6 may be associated with neurodevelopmental
delay at age 2.
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INTRODUCTION
There is accumulating evidence to support the hypothesis that neurodevelopmental outcomes
after preterm birth are influenced by both genetic and environmental factors. The fetal
inflammatory response syndrome (FIRS) is a multisystem disorder that has been associated
with preterm birth, cerebral white-matter damage (periventricular leukomalacia), and cerebral
palsy (CP).1–3 Fetal proinflammatory cytokines IL6, IL1-β and tumor necrosis factor (TNF)-
α have been associated with fetal/neonatal central nervous system (CNS) injury.3 Further,
polymorphisms in genes related to cytokine function (TNF-α, mannose-binding lectin, IL8 and
lymphotoxin-α) have been associated with an increased risk of CP in recent studies.4, 5
Perinatal thromboembolic events are also increasingly recognized as a cause of neurologic
disabilities such as CP, epilepsy, and other cognitive abnormalities.6 Polymorphisms in genes
related to thrombosis or thrombolysis (factor V Leiden, prothrombin gene mutation G20210A,
Factor VII, plasminogen activator inhibitor I and methylenetetrahydrofolate reductase) have
been associated with an increased risk of CP.7, 8 The interaction between the inflammation
and coagulation pathways may be important to the mechanism of fetal CNS injury. Perinatal
arterial ischemic stroke (a common cause of hemiplegic CP) has been linked to several
independent maternal risk factors, including chorioamnionitis.9 There is compelling evidence
that activated coagulation factors contribute to neonatal white matter damage through enhanced
inflammation, rather than occlusion of cerebral blood vessels.10
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While previous studies suggest that certain single nucleotide polymorphisms (SNPs) in
inflammation and coagulation pathway genes increase vulnerability to cerebral palsy, it is
uncertain whether SNPs in one or both of these pathways are associated with other forms of
neurodevelopmental delay. We hypothesized that children with neurodevelopmental delay at
age 2, when compared to children with normal neurodevelopment, have differences in
inflammation and/or coagulation pathways gene SNPs.
MATERIALS AND METHODS
Subjects
The subjects evaluated were children enrolled in the NICHD Maternal Fetal Medicine Units
(MFMU) Network randomized, double-masked, placebo-controlled, multicenter clinical trial
of single- versus multiple-course antenatal corticosteroids. The primary aim of this trial was
to assess the clinical efficacy and safety of repeated doses of antenatal corticosteroids in
pregnancies at risk for preterm birth. The details of the trial, which was conducted between
2000 and 2003, have been previously reported. 11, 12
A secondary aim of the MFMU Network antenatal corticosteroid trial was the correlation of
steroid regimen with neurodevelopmental outcomes as assessed by the Bayley Scales of Infant
Development, second edition, at age 2 years.12 The Bayley Scales consist of mental and
psychomotor developmental indices (MDI and PDI). A Bayley score of 85 is 1 SD below the
mean and consistent with mild neurodevelopmental delay. A Bayley score of 70 is 2 SD below
the mean and consistent with more significant delay. Placental samples and fetal cord serum
were collected in a subset of subjects enrolled in the MFMU Network antenatal corticosteroid
trial per study protocol.
Our secondary analysis aimed to evaluate the association between SNPs in fetal inflammation
and coagulation pathway genes and neurodevelopmental delay at age 2 years. Inclusion criteria
consisted of 1) maternal enrollment in the MFMU Network antenatal corticosteroid trial, 2)
Bayley scores at age 2 years and, 3) DNA extracted from placental samples or fetal cord serum.
Cases were children with mental and/or psychomotor delay, defined by a Bayley MDI and/or
PDI <85 at age 2 years. Cerebral palsy cases (as defined in the primary trial)11 were excluded
from the analysis in order to test our hypothesis of an association between inflammation and
coagulation gene SNPs and neurodevelopmental delay at age 2 in the absence of cerebral palsy.
Controls were children with normal neurodevelopment, defined by Bayley MDI and PDI ≥85.
The study group is illustrated in Figure 1. From the original steroid trial, 583 children were
discharged alive. Of these, 4 died between discharge and follow-up, and 23 were not available
because they were born at a center that discontinued participation in the MFMU Network in
2001. Of the remaining 556 children who were available for follow-up, 459 (83%) had Bayley
scores at age 2–3 years. After exclusion of CP cases (n=7), 452 children were eligible for
participation in our analysis. There were 40 twin pairs in the original steroid trial. For this
study, one twin from each pair (n=40) was randomly excluded to avoid the issue of including
related individuals in the analysis. Of the remaining 412 infants, DNA from placental tissues
and/or fetal serum was available for 272 infants, 125 cases and 147 controls.
After IRB review, this study was determined to be exempt from IRB approval procedures
secondary to de-identification of data and study samples prior to this analysis.
DNA Extraction
DNA was extracted from placental samples and/or umbilical cord serum collected at the time
of delivery. Placental samples were either fresh (n=145) or formalin-fixed and paraffin-
embedded (n=92). DNA was extracted from approximately 0.7 gm of fresh placental tissue
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using the PureGene DNA Purification System (Qiagen, Valencia, CA) as per the
manufacturer’s protocols. DNA from the formalin-fixed paraffin-embedded samples was
extracted from 3–6, five micron sections obtained from the paraffin block and isolated using
the PureGene DNA Purification System as per the manufacturer’s protocols. DNA was also
extracted from umbilical cord serum samples (n=190). Briefly, 250–1000 μL of cord serum
was centrifuged at 10,000 × g for 10 minutes to pellet any cells in the sera. The supernatant
was discarded and DNA was extracted with the same procedure used for placental samples.
Selection of SNPs for Genotyping
We selected 46 SNPs in 27 inflammation and coagulation genes based on the available literature
and hypothesized causal pathways. We also included SNPs that have been reported to be
associated with cerebral palsy. 4, 5, 8, 13 The SNPs included in our custom multiplex assay are
shown in Table 1.
Genotyping
The 48-Plex GenomeLab™ SNPStream® Genotyping System and accompanying automated
genotype calling software (Beckman Coulter, Fullerton, CA) was used for genotyping.
Polymerase-chain-reaction (PCR) assays and extension primers for these SNPs were designed
with the use of Beckman Coulter’s Autoprimer multiplex primer design engine
(www.Autoprimer.com). PCR and extension reactions were performed according to the
manufacturer’s instructions. Controls were appropriately included in each 384-well plate.
Researchers and laboratory personnel were blinded to the case/control status of the biologic
samples.
When DNA was available from both placenta and serum, the placental samples were used
preferentially secondary to higher quality DNA. In subjects with a placental tissue genotyping
success rate of <85%, the serum samples were also genotyped with a goal of increasing the
number of SNP results. In 25 subjects with both placental tissue and sera genotyped,
manufacturer’s automated allele calling resulted in at least one discordant SNP between the
two samples. Comparison of data quality allowed a correct genotype to be easily identified in
most cases. If the subject’s correct genotype could not be easily identified, no genotype was
reported for that SNP. In all but one case, it was the serum data that was questionable secondary
to the low intensity of the genotype signal due to poor quality and low concentration of the
extracted DNA. In 3 subjects, the data for both serum and placental samples was strong, but
many SNPs were discordant. These 3 subjects were removed from the analysis. Because the
serum samples tended to have lower DNA quality, the automated genotype results were
individually reviewed. If data quality did not allow for a clear genotype determination for a
given serum sample, no genotype was reported.
Statistics
Demographic and clinical characteristics of cases and controls were compared using the Chi-
square or Fisher’s Exact test for categorical variables and the Wilcoxon Rank Sum test for
continuous variables. Differences in allele and genotype frequencies between cases and
controls were tested for each SNP with the use of the Chi-square or Fisher’s exact tests, as
appropriate. SNPs found to be significantly related to MDI and/or PDI <85 in the univariate
analyses (p<0.05) were further analyzed using multiple logistic regression modeling.
Genotypes were included as covariates in a series of regression models assuming either an
additive, dominant, or recessive genetic pattern. The additive model assumes that having 2
copies of minor allele has twice the effect of having 1 copy, the dominant model assumes that
having at least one copy of the minor allele is sufficient for disease, and the recessive model
assumes that two copies of the minor allele are needed for disease. Other covariates included
gestational age at delivery, small for gestational age (SGA) status (based on a birth weight less
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than the 10th percentile of published standards)14, gender, steroid treatment group, race,
smoking, and maternal level of education. Of the three ways of examining genotype, the
regression model that had the highest likelihood score was considered to be the best-fitting
model for the respective SNP. The sample size and the rarity of some genotypes and phenotypes
limited further modeling of interactions.
Tests for Hardy-Weinberg equilibrium (chi-square or Fisher’s exact) were performed on
control subjects for each SNP significant in the univariate analysis. As this was an exploratory
study, no adjustments were made for multiple comparisons and all comparisons are reported.
A p-value of less than 0.05 was considered to be statistically significant. All calculations were
performed using SAS software (SAS Institute, Inc, Cary, NC).
RESULTS
The demographic and clinical characteristics of those included vs. excluded from our study
based on availability of biologic samples for DNA analysis are shown in Table 2. Subjects
excluded from our study were born at an earlier gestational age (p=0.01), had a lower
birthweight (p=0.01) and were more likely to have received multiple courses of antenatal
corticosteroids (p=0.007). The demographic and clinical characteristics of our study subjects
are shown in Table 3. Significant differences between cases and controls were observed for
race/ethnicity (p<0.001) and maternal education (p=0.01).
We achieved DNA PCR amplification for 35 of the 46 SNPs included on the custom multiplex
assay (76%). Primer interaction, a common problem in multiplex assays, likely accounted for
the PCR failures that were observed. The average genotyping call rate per subject sample was
63%. This genotyping call rate is reflective of the DNA degradation that was observed among
the formalin-fixed paraffin-embedded placental samples.
Table 4 lists allele and genotype frequencies for the 35 SNPs among case and control subjects.
Allele frequencies were significantly different between cases and controls for IL1-β –511
(p=0.009), IL4R 148 (p=0.03), IL6 -174 (p=0.02), and IL6 -176 (p=0.007). Genotype
frequencies were significantly different between cases and controls for IL1-β-511(p=0.03) and
IL6 -174 (p=0.04).
SNPs found to be significantly related (p<0.05) to MDI and/or PDI <85 in the univariate
analyses (IL1-β –511, IL4R 148, IL6 -174 and -176) were further analyzed using multiple
logistic regression modeling. Results of the logistic regression analysis for association of
genotype with neurodevelopmental delay at age 2 years are presented in Table 5. Carriers of
the IL1-β-511 and IL6 -176 minor alleles were more likely (OR 3.1, 95% CI 1.2–8.2, and 2.2,
95% CI 1.2–3.9, respectively) to have neurodevelopmental delay than control subjects, after
adjustment for gestational age at delivery, SGA, gender, steroid treatment group, race,
smoking, and maternal level of education. Carriers of the IL4R 148 minor allele were less likely
to have neurodevelopmental delay (OR 0.6, 95% CI 0.4–0.9). The IL6 -174 genotype was not
significantly associated with neurodevelopmental delay in the logistic regression analysis.
When various genotype models were tested, the best-fitting model was recessive for IL1-β –
511, dominant for IL6 -176, and additive for IL4R 148.
In the control group, each SNP that was significant in the univariate analysis was in Hardy-
Weinberg equilibrium, with the exception of IL6 -176 (p<0.0001).
COMMENT
We used a candidate gene association approach to investigate the role of inflammation and
coagulation pathway gene SNPs in cognitive development in pregnancies at-risk for preterm
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birth. Our results suggest an association between SNPs in IL-1β, IL6, and IL4R and
neurodevelopmental delay at age 2. Biologically this is plausible, as inflammation and/or
coagulation pathway-mediated fetal/neonatal brain injury could occur to a milder extent than
necessary for a diagnosis of cerebral palsy and could also occur outside the vulnerable motor
pathways of the developing brain.
Perinatal concentrations of the proinflammatory cytokines IL1-β and IL6 have been shown to
correlate directly with the development of periventricular white matter injury and subsequent
cerebral palsy.3 The IL1-β-511 SNP is in the enhancer-promoter region of the gene and the A
allele has been associated with higher levels of IL1-β.15, 16 The IL6 -174 and -176 SNPs are
also in the enhancer-promotor region of the gene, and although functional assays have been
somewhat conflicting, the G allele at position -174 has been associated with a stronger IL6
response.17, 18 SNPs that are capable of altering circulating cytokine levels have been
associated with CP, either directly through cytokine-mediated brain damage or indirectly
through altered immune response to infection.4, 5, 8 Our study suggests that proinflammatory
cytokine gene SNPs may also increase the risk of subsequent neurodevelopmental delay.
The IL4R 148 (ile50val) polymorphism is in the extracellular domain of the alpha chain of the
IL4R complex. The IL4R plays a critical role in IL4 binding and signal transduction, and
therefore IL4-mediated IgE production and Th2 inflammatory reactions. Variants in IL4Rα
have been reported to be associated with atopic phenotypes, leading to the hypothesis that the
IL4R alpha chain is a major atopy locus. 19–22 Our study suggests that genetic alterations to
the extracellular domain of IL4R may contribute to neurodevelopmental outcomes in
pregnancies at high risk for preterm birth.
Although polymorphisms in genes related to thrombosis or thrombolysis have been associated
with an increased risk of CP,7, 8 coagulation pathway gene polymorphisms were not associated
with neurodevelopmental delay in this study. Since the interaction between the inflammation
and coagulation pathways may be critical to the mechanism of fetal CNS injury, studies with
sufficient power to evaluate gene-gene interactions should be pursued.
It should be noted that neurodevelopmental testing at age 2 is of limited predictive value,
particularly for subtle deficits. Whether inflammation gene variants have any longer-term
neurocognitive effects of clinical significance is uncertain, and cannot be extrapolated from
this data.
Genes or SNPs in linkage disequilibrium with those we have identified, rather than the genes
and SNPs that we report, may be the actual causative variants associated with
neurodevelopmental outcomes. In addition, missing genotyping data and sample size may
result in true genotype-phenotype associations being missed. Further studies in other
populations are needed to confirm or refute the genetic associations described.
We acknowledge that the observed associations between genotype and neurodevelopmental
delay may be due to chance as multiple analyses increase the likelihood of identifying chance
statistical associations. However, multiple previous studies have demonstrated a strong
association between proinflammatory cytokines and fetal/neonatal central nervous system
injury. In addition, variation in the IL6 gene has been shown to be associated with impaired
cognitive development in children born prematurely. 23 These studies lend support and biologic
plausibility to our findings.
Sample size did not permit analysis with stratification by race/ethnicity, and we acknowledge
this as a study limitation. This may have been addressed by genotyping of Ancestry Informative
Markers (AIMS), which would have allowed us to control and adjust for racial admixture.24
However, this was cost-prohibitive for this exploratory analysis. The sample size and lack of
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placental pathology also prohibited analysis of the interaction of genotype with maternal/
intrauterine infection and neonatal sepsis, a gene-environment interaction of obvious interest.
The demographic and clinical characteristics of subjects included vs. excluded in this analysis
(Table 2) suggest that our subjects are not entirely representative of the original steroid trial.
We speculate that the differences between subjects included versus excluded may reflect more
difficult sample collection in subjects born at an earlier gestational age (and lower birth weight).
In these babies, delivery circumstances and resuscitation efforts may have negatively
influenced the ability to collect adequate biologic specimens. We are uncertain as to why
subjects that were excluded were more likely to have received antenatal multiple-course
steroids. These subject characteristics were included in our regression analysis, and are unlikely
to be a significant source of bias.
The risk of central nervous system injury in preterm infants is influenced by complex gene-
environment interactions that are not yet well understood. The strengths of this study include
the evaluation of a large cohort of infants at risk for preterm birth with appropriate controls
and well-characterized obstetrical and neurodevelopmental outcomes. This study adds to the
current evidence that certain inflammation gene variants may contribute to adverse
neurodevelopmental outcomes and suggests that further investigation of genetic
polymorphisms as contributors to susceptibility to neurodevelopmental delay in preterm
infants is warranted. Ultimately, a better understanding of genetic factors that predispose to
these outcomes may lead to identification of new prevention strategies and future prevention/
intervention trials.
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Figure 1. Identification of Cases and Controls
From the original steroid trial, 583 children were discharged alive. Of these, 4 died between
discharge and follow-up and 23 were not available because they were born at a center that
discontinued participation in the MFMU Network in 2001; cases and controls were selected
from the remaining 556 children who were available for follow-up.
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Table 1
Single Nucleotide Polymorphisms Studied
Gene Symbol Polymorphism RS Number
Lymphotoxin-α (Tumor Necrosis Factor-β) LTA thr26asn(C/A) rs1041981*





Tumor Necrosis Factor-α TNF −308(G/A) rs1800629
−376(G/A) rs1800750*
−238(G/A) rs361525
Tumor Necrosis Factor Receptor Superfamily Member 6 TNFRSF6 −670(G/A) rs1800682
Interleukin 1-α IL1A −889(C/T) rs1800587
Interleukin 1-β IL1B +3962(C/T) rs12621220
−511(A/G) rs16944
Interleukin 1 Type 1 Receptor IL1RN +970(C/T) rs3917365
Interleukin 4 IL4 −590(C/T) rs2234648
582(A/G) rs35648164
Interleukin 4 Receptor IL4R gln576arg(A/G) rs1801275
ile50val(A/G) rs1805010
Interleukin 5 Receptor-α IL5RA −80(G/A) rs2290608
Interleukin 6 IL6 −174(G/C) rs1800795
−176(G/C) rs2234683
Interleukin 9 IL9 553(A/C) rs2066760
thr113met(T/C) rs2069885*
Interleukin 10 IL10 −819(C/T) rs1800871*
−1082(G/A) rs1800896
Interleukin 13 IL13 arg130gln(T/C) rs20541
Factor II F2 20210(G/A) rs1799963
Factor V Leiden F5 arg506gln(A/G) rs6025
arg353gln(T/C) rs6046*
Factor XIII F13 val34leu(T/G) rs5985
Methylenetetrahydrofolate Reductase MTHFR 1298(A/C) rs1801131
677(C/T) rs1801133
Thrombomodulin THBD 1418(C/T) rs1042579*
Plasminogen Activator Inhibitor 1 PAI1 +11053(G/T) rs7242*
Fibrinogen-β Polypeptide Chain FGB −455(G/A) rs1800790*
Thrombin Activatable Fibrinolysis Inhib. TAFI 1040(C/T) rs1926447
Platelet Glycoprotein Ia (Integrin, α2) ITGA2 873(G/A) rs1062535*
β-Adrenergic Receptor ADRB2 arg16gly(A/G) rs1042713
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Gene Symbol Polymorphism RS Number
gln27glu(C/G) rs1042714
Nitric Oxide Synthase 3, Endothelial NOS3 −690(C/T) rs3918226
glu298asp(T/G) rs1799983
−922(A/G) rs1800779
Selectin P SELP val640leu(T/G) rs6133
thr756pro(C/A) rs6136
Transforming Growth Factor-β1 TGFB1 −800(G/A) rs1800468
−509(C/T) rs1800469
*
PCR amplification was not successful
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Table 2
Demographic and Clinical Characteristics of Children Included vs. Excluded
Characteristic Included Excluded* P
Subjects, n 272 180
Gender, n (%)
 Male 143 (52.6) 89 (49.4) 0.51
 Female 129 (47.4) 91 (50.6)
Race/ethnicity†, n (%)
 White 92 (33.8) 37 (35.2) 0.59
 Black 104 (38.2) 44 (41.9)
 Other 76 (27.9) 24 (22.9)
GA at delivery†, mean ± SD, wk 35.2 ± 3.8 34.2 ± 3.7 0.01
GA at delivery†, n (%)
 ≥37 wks 108 (39.7) 27 (25.7) 0.03
 32–36 wks 111 (40.8) 49 (46.7)
 <32 wks 53 (19.5) 29 (27.6)
Birth weight, mean ± SD, gm 2396.3 ± 778.7 2059.4 ± 721.4 0.01
Neurodevelopment, n (%)
 MDI and/or PDI < 85 125 (46.0) 86 (47.8) 0.94
 MDI and/or PDI < 70 50 (18.4) 37 (20.6) 0.86
Chorioamnionitis†, n (%) 8 (2.9) 3 (2.9) 1.00
Maternal tobacco use†, n (%) 55 (20.2) 25 (23.8) 0.44
Antenatal multiple-course steroids†, n (%) 126 (46.3) 65 (61.9) 0.007
Maternal education†, mean ± SD, y 12.3 ± 2.7 12.3 ± 2.2 0.55
*
One twin from each pair (n=40) and subjects lacking DNA for analysis (n=140) were excluded
†
272 pregnancies included vs. 105 pregnancies excluded
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Table 3
Demographic and Clinical Characteristics of Children with Neurodevelopmental Delay (Cases) vs. Controls
Characteristic Cases Controls P
Study sample, n 125 147
Gender, n (%)
 Male 69 (55.2) 74 (50.3) 0.42
 Female 56 (44.8) 73 (49.7)
Race/ethnicity, n (%)
 White 25 (20.0) 67 (45.6) <0.001
 Black 55 (44.0) 49 (33.3)
 Other 45 (36.0) 31 (21.1)
GA at delivery, mean ± SD, wk 35.4 ± 3.7 35.0 ± 3.9 0.36
GA at delivery, n (%)
 ≥ 37 wks 53 (42.4) 55 (37.4) 0.53
 32–36 wks 51 (40.8) 60 (40.8)
 <32 wks 21 (16.8) 32 (21.8)
Birth weight, mean ± SD, kg 2383.4 ± 719.2 2407.2 ± 828.2 0.83
Neurodevelopment, n (%)
 MDI and PDI ≥ 85 0 147 (100)
 MDI and/or PDI <85 125 (100) 0
 MDI and/or PDI <70 50 (40.0) 0
Chorioamnionitis, n (%) 3 (2.4) 5 (3.4) 0.73
Maternal tobacco use, n (%) 22 (17.6) 33 (22.4) 0.32
Antenatal multiple-course steroids, n (%) 54 (43.2) 72 (49.0) 0.34
Maternal education, y 11.8 ± 2.7 12.6 ± 2.6 0.01
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Table 5
Logistic Regression Analysis for Association of Genotype with Neurodevelopmental Delay at Age 2 Years*
Gene Polymorphism RS Number OR (95% CI)† Best Model
IL1-β −511A/G 16944 3.1 (1.2–8.2) Recessive
IL4-R Ile50Val, 148 (A/G) 1805010 0.6 (0.4–0.9) Additive
IL6 −176G/C 2234683 2.2 (1.2–3.9) Dominant
IL6 −174G/C 1800795 0.5 (0.2–1.2) Dominant
*
Covariates included gestational age at delivery, small for gestational age (SGA) status, gender, steroid treatment group, race, smoking, and maternal
level of education.
†
OR, odds ratio; CI, confidence interval.
Am J Obstet Gynecol. Author manuscript; available in PMC 2011 July 1.
